Galaxi的个人主页 - 老虎社区

Galaxi

Galaxi

暂无个人介绍

IP属地：未知

1关注

2粉丝

0主题

0勋章

2022-01-27

[微笑]

抱歉，原内容已删除

2022-01-27

[微笑]

抱歉，原内容已删除

2022-01-05

[微笑]

抱歉，原内容已删除

2021-12-23

Great

Wall St mints strong gains on rosy economic data, encouraging Omicron update

2021-12-23

What happened

Biogen shares fell 1.2% in early trading

2021-12-17

Agree it will

抱歉，原内容已删除

2021-12-17

[龇牙]

5 Stocks Insiders Are Selling

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4088564397232090","uuid":"4088564397232090","gmtCreate":1625462081219,"gmtModify":1635513502672,"name":"Galaxi","pinyin":"galaxi","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":1,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.27","exceedPercentage":"80.28%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.01.24","exceedPercentage":"60.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":639686788,"gmtCreate":1643275829801,"gmtModify":1643275829910,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/639686788","repostId":"1177706022","repostType":4,"isVote":1,"tweetType":1,"viewCount":806,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":639686298,"gmtCreate":1643275782363,"gmtModify":1643275782439,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/639686298","repostId":"1177706022","repostType":4,"isVote":1,"tweetType":1,"viewCount":1030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695801853,"gmtCreate":1641386879506,"gmtModify":1641386879673,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/695801853","repostId":"2201480235","repostType":4,"isVote":1,"tweetType":1,"viewCount":872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691468385,"gmtCreate":1640228624992,"gmtModify":1640228768616,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691468385","repostId":"2193113147","repostType":4,"repost":{"id":"2193113147","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213688,"share":"https://www.laohu8.com/m/news/2193113147?lang=&edition=full","pubTime":"2021-12-23 06:54","market":"us","language":"en","title":"Wall St mints strong gains on rosy economic data, encouraging Omicron update","url":"https://stock-news.laohu8.com/highlight/detail?id=2193113147","media":"Reuters","summary":"* Tesla jumps as CEO Musk says he has sold 'enough' stock. * Pfizer rises as oral COVID-19 pill wins approval. Dec 22  - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.The S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of","content":"<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St mints strong gains on rosy economic data, encouraging Omicron update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St mints strong gains on rosy economic data, encouraging Omicron update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","COMP":"Compass, Inc.","PFE":"辉瑞",".DJI":"道琼斯","BK4568":"美国抗疫概念","TSLA":"特斯拉",".IXIC":"NASDAQ Composite","BK4007":"制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193113147","content_text":"* Consumer confidence index increases in December\n* U.S. Q3 economic growth revised slightly higher\n* Tesla jumps as CEO Musk says he has sold 'enough' stock\n* Pfizer rises as oral COVID-19 pill wins approval\n* Indexes up: Dow 0.74%, S&P 1.02%, Nasdaq 1.18% \nDec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.\nThe S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.\nA South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.\n“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.\nThe Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.\nAll major S&P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.\nTesla Inc shares rose 7.5%, boosting the S&P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.\nU.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.\nOther reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.\nIn another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.\nThe benchmark S&P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.\nThe market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”\nAdvancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.\nThe S&P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.\nAbout 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":793,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691203813,"gmtCreate":1640189565031,"gmtModify":1640189565031,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"What happened","listText":"What happened","text":"What happened","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691203813","repostId":"1104039472","repostType":4,"repost":{"id":"1104039472","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640184691,"share":"https://www.laohu8.com/m/news/1104039472?lang=&edition=full","pubTime":"2021-12-22 22:51","market":"us","language":"en","title":"Biogen shares fell 1.2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104039472","media":"Tiger Newspress","summary":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inc","content":"<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen shares fell 1.2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen shares fell 1.2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104039472","content_text":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":997,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699385788,"gmtCreate":1639749919976,"gmtModify":1639749919976,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"Agree it will","listText":"Agree it will","text":"Agree it will","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699385788","repostId":"2192978346","repostType":4,"isVote":1,"tweetType":1,"viewCount":988,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699388028,"gmtCreate":1639749606635,"gmtModify":1639749606635,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"[龇牙]&nbsp;","listText":"[龇牙]&nbsp;","text":"[龇牙]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699388028","repostId":"1116116501","repostType":4,"repost":{"id":"1116116501","pubTimestamp":1639745427,"share":"https://www.laohu8.com/m/news/1116116501?lang=&edition=full","pubTime":"2021-12-17 20:50","market":"us","language":"en","title":"5 Stocks Insiders Are Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1116116501","media":"Benzinga","summary":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view t","content":"<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.</p>\n<p>Below is a look at a few recent notable insider sales.</p>\n<p><b>LegalZoom.com</b></p>\n<ul>\n <li><b>The Trade:LegalZoom.com, Inc.</b>&nbsp;Chief Financial Officer Bertram Noel Watson&nbsp;<i>disposed a total of 69466 shares</i>&nbsp;at an average price of $15.65. The insider received $1,087,351.30 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Morgan Stanley maintained LegalZoom.com with an Equal-Weight and lowered the price target from $28 to $19.</li>\n <li><b>What LegalZoom.com Does:</b>LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States</li>\n</ul>\n<p><b>Arvinas</b></p>\n<ul>\n <li><b>The Trade:Arvinas, Inc.</b>&nbsp;Director Liam Ratcliffe&nbsp;<i>sold a total of 355705 shares</i>&nbsp;at an average price of $67.00. The insider received $23,833,380.68 from selling those shares.</li>\n <li><b>What’s Happening:</b>Arvinas and Pfizer recently posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).</li>\n <li><b>What Arvinas Does:</b>Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.</li>\n</ul>\n<p><b>Marvell Technology</b></p>\n<ul>\n <li><b>The Trade:Marvell Technology, Inc.</b>&nbsp;CEO and President Matthew Murphy&nbsp;<i>sold a total of 30000 shares</i>&nbsp;at an average price of $85.98. The insider received $2,579,400.00 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Marvell recently introduced industry's first 50G PAM4 DSP chipset for next generation 5G RAN optical fronthaul.</li>\n <li><b>What Marvell Technology Does:</b>Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications.</li>\n</ul>\n<p><b>Hewlett Packard Enterprise</b></p>\n<ul>\n <li><b>The Trade:Hewlett Packard Enterprise Company</b>&nbsp;SVP &amp; GM, HPC &amp; AI Business Group Justin Hotard&nbsp;<i>sold a total of 40012 shares</i>&nbsp;at an average price of $14.55. The insider received $582,174.60 from selling those shares.</li>\n <li><b>What’s Happening:</b>Hewlett Packard Enterprise recently reported worse-than-expected Q4 sales results.</li>\n <li><b>What Hewlett Packard Enterprise Does:</b>Hewlett Packard Enterprise is a supplier of IT infrastructure products and services. The company operates as three major segments.</li>\n</ul>\n<p><b>Ameren</b></p>\n<ul>\n <li><b>The Trade:Ameren Corporation</b>&nbsp;Chairman, President and CEO Warner L Baxter<i>sold a total of 68300 shares</i>&nbsp;at an average price of $87.31. The insider received $4,976,670.00 from selling those shares.</li>\n <li><b>What’s Happening:</b>BMO Capital recently maintained Ameren with an Outperform and raised the price target from $85 to $95.</li>\n <li><b>What Ameren Does:</b>Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves nearly 2.5 million electricity customers and roughly 1.0 million natural gas customers.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks Insiders Are Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks Insiders Are Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HPE":"慧与科技","ARVN":"Arvinas Holding Company LLC","LZ":"LegalZoom.com, Inc","AEE":"阿曼瑞恩","MRVL":"迈威尔科技"},"source_url":"https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116116501","content_text":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.\nBelow is a look at a few recent notable insider sales.\nLegalZoom.com\n\nThe Trade:LegalZoom.com, Inc. Chief Financial Officer Bertram Noel Watson disposed a total of 69466 shares at an average price of $15.65. The insider received $1,087,351.30 as a result of the transaction.\nWhat’s Happening:Morgan Stanley maintained LegalZoom.com with an Equal-Weight and lowered the price target from $28 to $19.\nWhat LegalZoom.com Does:LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States\n\nArvinas\n\nThe Trade:Arvinas, Inc. Director Liam Ratcliffe sold a total of 355705 shares at an average price of $67.00. The insider received $23,833,380.68 from selling those shares.\nWhat’s Happening:Arvinas and Pfizer recently posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).\nWhat Arvinas Does:Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.\n\nMarvell Technology\n\nThe Trade:Marvell Technology, Inc. CEO and President Matthew Murphy sold a total of 30000 shares at an average price of $85.98. The insider received $2,579,400.00 as a result of the transaction.\nWhat’s Happening:Marvell recently introduced industry's first 50G PAM4 DSP chipset for next generation 5G RAN optical fronthaul.\nWhat Marvell Technology Does:Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications.\n\nHewlett Packard Enterprise\n\nThe Trade:Hewlett Packard Enterprise Company SVP & GM, HPC & AI Business Group Justin Hotard sold a total of 40012 shares at an average price of $14.55. The insider received $582,174.60 from selling those shares.\nWhat’s Happening:Hewlett Packard Enterprise recently reported worse-than-expected Q4 sales results.\nWhat Hewlett Packard Enterprise Does:Hewlett Packard Enterprise is a supplier of IT infrastructure products and services. The company operates as three major segments.\n\nAmeren\n\nThe Trade:Ameren Corporation Chairman, President and CEO Warner L Baxtersold a total of 68300 shares at an average price of $87.31. The insider received $4,976,670.00 from selling those shares.\nWhat’s Happening:BMO Capital recently maintained Ameren with an Outperform and raised the price target from $85 to $95.\nWhat Ameren Does:Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves nearly 2.5 million electricity customers and roughly 1.0 million natural gas customers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":639686788,"gmtCreate":1643275829801,"gmtModify":1643275829910,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/639686788","repostId":"1177706022","repostType":4,"repost":{"id":"1177706022","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643275472,"share":"https://www.laohu8.com/m/news/1177706022?lang=&edition=full","pubTime":"2022-01-27 17:24","market":"us","language":"en","title":"Lending Club Tumbled Over 13% in Premarket Trading as Its Q1 Net Income Could Slip from Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=1177706022","media":"Tiger Newspress","summary":"Lending Club tumbled over 13% in premarket trading as its Q1 net income could slip from Q4. It repor","content":"<html><head></head><body><p>Lending Club tumbled over 13% in premarket trading as its Q1 net income could slip from Q4.</p><p> <img src=\"https://static.tigerbbs.com/b2328e3e313de301e09268dc126acc76\" tg-width=\"772\" tg-height=\"565\" width=\"100%\" height=\"auto\"/></p><p>It reported Q4 diluted EPS of $0.27, compared with a loss of $0.29 a year ago.</p><p>Revenue climbed to $262.2 million from $75.5 million. The Street called for $246.2 million.</p><p>It expected revenue of $255 million to $265 million for Q1 and $1.1 billion to $1.2 billion for full-year 2022, versus the respective Street views of $255.5 million and $1.14 billion.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lending Club Tumbled Over 13% in Premarket Trading as Its Q1 Net Income Could Slip from Q4</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLending Club Tumbled Over 13% in Premarket Trading as Its Q1 Net Income Could Slip from Q4\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-27 17:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Lending Club tumbled over 13% in premarket trading as its Q1 net income could slip from Q4.</p><p> <img src=\"https://static.tigerbbs.com/b2328e3e313de301e09268dc126acc76\" tg-width=\"772\" tg-height=\"565\" width=\"100%\" height=\"auto\"/></p><p>It reported Q4 diluted EPS of $0.27, compared with a loss of $0.29 a year ago.</p><p>Revenue climbed to $262.2 million from $75.5 million. The Street called for $246.2 million.</p><p>It expected revenue of $255 million to $265 million for Q1 and $1.1 billion to $1.2 billion for full-year 2022, versus the respective Street views of $255.5 million and $1.14 billion.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LC":"LendingClub"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177706022","content_text":"Lending Club tumbled over 13% in premarket trading as its Q1 net income could slip from Q4. It reported Q4 diluted EPS of $0.27, compared with a loss of $0.29 a year ago.Revenue climbed to $262.2 million from $75.5 million. The Street called for $246.2 million.It expected revenue of $255 million to $265 million for Q1 and $1.1 billion to $1.2 billion for full-year 2022, versus the respective Street views of $255.5 million and $1.14 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":806,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691468385,"gmtCreate":1640228624992,"gmtModify":1640228768616,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691468385","repostId":"2193113147","repostType":4,"repost":{"id":"2193113147","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213688,"share":"https://www.laohu8.com/m/news/2193113147?lang=&edition=full","pubTime":"2021-12-23 06:54","market":"us","language":"en","title":"Wall St mints strong gains on rosy economic data, encouraging Omicron update","url":"https://stock-news.laohu8.com/highlight/detail?id=2193113147","media":"Reuters","summary":"* Tesla jumps as CEO Musk says he has sold 'enough' stock. * Pfizer rises as oral COVID-19 pill wins approval. Dec 22  - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.The S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of","content":"<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St mints strong gains on rosy economic data, encouraging Omicron update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St mints strong gains on rosy economic data, encouraging Omicron update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","COMP":"Compass, Inc.","PFE":"辉瑞",".DJI":"道琼斯","BK4568":"美国抗疫概念","TSLA":"特斯拉",".IXIC":"NASDAQ Composite","BK4007":"制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193113147","content_text":"* Consumer confidence index increases in December\n* U.S. Q3 economic growth revised slightly higher\n* Tesla jumps as CEO Musk says he has sold 'enough' stock\n* Pfizer rises as oral COVID-19 pill wins approval\n* Indexes up: Dow 0.74%, S&P 1.02%, Nasdaq 1.18% \nDec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.\nThe S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.\nA South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.\n“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.\nThe Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.\nAll major S&P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.\nTesla Inc shares rose 7.5%, boosting the S&P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.\nU.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.\nOther reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.\nIn another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.\nThe benchmark S&P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.\nThe market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”\nAdvancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.\nThe S&P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.\nAbout 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":793,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":639686298,"gmtCreate":1643275782363,"gmtModify":1643275782439,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/639686298","repostId":"1177706022","repostType":4,"isVote":1,"tweetType":1,"viewCount":1030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695801853,"gmtCreate":1641386879506,"gmtModify":1641386879673,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/695801853","repostId":"2201480235","repostType":4,"repost":{"id":"2201480235","pubTimestamp":1641383501,"share":"https://www.laohu8.com/m/news/2201480235?lang=&edition=full","pubTime":"2022-01-05 19:51","market":"us","language":"en","title":"It's Time to Sell 1 of Warren Buffett's Favorite Stocks in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2201480235","media":"Motley Fool","summary":"Warren Buffett has held American Express since the 1960s, but it may be time to let go.","content":"<html><head></head><body><p>Warren Buffett is one of the greatest investors of all time, so it certainly grabs your attention when he has held a stock for almost 60 years. Credit card company <b>American Express</b> (NYSE:AXP) has become one of Warren Buffett&#39;s most significant holdings -- the stake is worth roughly $25 billion and is more than 8% of <b>Berkshire Hathaway</b>&#39;s portfolio, Buffett&#39;s holding company.</p><p>But the past can&#39;t speak for the future, and there are numerous signs that American Express could be past its glory days. Here are three reasons why 2022 could finally be the year to sell American Express.</p><h2>1. Not enough growth</h2><p>Warren Buffett originally bought his stake in American Express in the early 1960s when the young company got caught up in a Salad Oil scandal that scared the market. He purchased 5% of the company for approximately $20 million, a stake that is worth billions today.</p><p>Over six decades since then, American Express has evolved into one of the most iconic credit card brands globally. However, as a large company today with a $126 billion market cap, American Express&#39; best days could be behind it.</p><p><img src=\"https://static.tigerbbs.com/b6b3538eff405be9aa7a18c60a05f990\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>AXP Free Cash Flow data by YCharts</p><p>The company&#39;s key operating numbers have struggled over the past decade. Despite business essentially recovering to pre-pandemic levels, American Express has grown revenue a total of 34%, free cash flow 35%, and net income 57% over the past 10 years. This total growth breaks down into low-single-digit annual rates.</p><p>A valuation can influence a stock&#39;s returns, but American Express is likely to produce returns that mirror the pace the business is growing at over the long term. In other words, low-single-digit growth should eventually produce low-single-digit returns, which might not be good enough for many investors.</p><h2>2. Continued travel industry struggles</h2><p>American Express faces some challenges that could make it harder to rediscover a faster growth rate moving forward. The company&#39;s credit cards are popular for people who spend on travel and entertainment, which accounted for roughly a quarter of American Express&#39; U.S. business before the pandemic.</p><p>After travel began to rebound throughout 2020 as more of the population got vaccinated, the recent surge of the coronavirus omicron variant has already started to put a damper on travel once again.</p><p>Nobody can predict the future; what is known is that the COVID-19 virus continues mutating, producing new variants. While vaccines and other medications continue arriving to help combat the pandemic, nobody can be sure how the coronavirus will continue to impact travel spending in the near term.</p><p>American Express has reported that travel spending still lags pre-pandemic levels through three quarters of its 2021 fiscal year. Travel billings contributed 10% in the first quarter of 2021, 12% in the second quarter, and 14% in the third quarter. Investors will want to see fourth-quarter numbers to see how omicron has influenced travel. The coronavirus has been around for two years, so it&#39;s harder to discard the pandemic as a short-term business threat at this point.</p><h2>3. The buy now, pay later threat</h2><p>Looking further out, American Express remains threatened by the buy now, pay later (BNPL) competition rapidly heating up. Society is pivoting -- older consumers are quickly retiring, and younger generations such as Millennials are entering their prime earning and spending years.</p><p>American Express reported that Millennials and Gen Z are now driving growth in its business. Spending among this age group is up 40% compared to pre-pandemic 2019 levels, while other age groups are at 10% growth or less. This underlines the importance that these young customers have to the long-term success of American Express and its competition.</p><p>However, BNPL companies like <b>Affirm</b>, Klarna, and <b>Afterpay</b> have become very popular over the past year, especially with younger consumers. According to a study, 36% of BNPL users in the U.S. are under 25, and 41% are Millennials. Meanwhile, some experts predict that the BNPL market will grow 22% per year through 2028, and at least a chunk of this growth may be at the expense of traditional credit card companies like American Express.</p><h2>Get with the times</h2><p>American Express seems like an American classic that is past its prime. It may have staying power, continuing its low-single-digit growth rate, but in such a big consumer spending market, there should be better opportunities out there.</p><p>By contrast, Affirm is one of my favorites. It has partnered with many of the leading e-commerce sites in the U.S., and that could place it among the largest benefactors of BNPL&#39;s rapid growth moving forward.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>It's Time to Sell 1 of Warren Buffett's Favorite Stocks in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIt's Time to Sell 1 of Warren Buffett's Favorite Stocks in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 19:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/its-time-to-sell-1-of-warren-buffetts-favorite-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett is one of the greatest investors of all time, so it certainly grabs your attention when he has held a stock for almost 60 years. Credit card company American Express (NYSE:AXP) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/its-time-to-sell-1-of-warren-buffetts-favorite-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXP":"美国运通","BK4166":"消费信贷","BK4559":"巴菲特持仓"},"source_url":"https://www.fool.com/investing/2022/01/05/its-time-to-sell-1-of-warren-buffetts-favorite-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201480235","content_text":"Warren Buffett is one of the greatest investors of all time, so it certainly grabs your attention when he has held a stock for almost 60 years. Credit card company American Express (NYSE:AXP) has become one of Warren Buffett's most significant holdings -- the stake is worth roughly $25 billion and is more than 8% of Berkshire Hathaway's portfolio, Buffett's holding company.But the past can't speak for the future, and there are numerous signs that American Express could be past its glory days. Here are three reasons why 2022 could finally be the year to sell American Express.1. Not enough growthWarren Buffett originally bought his stake in American Express in the early 1960s when the young company got caught up in a Salad Oil scandal that scared the market. He purchased 5% of the company for approximately $20 million, a stake that is worth billions today.Over six decades since then, American Express has evolved into one of the most iconic credit card brands globally. However, as a large company today with a $126 billion market cap, American Express' best days could be behind it.AXP Free Cash Flow data by YChartsThe company's key operating numbers have struggled over the past decade. Despite business essentially recovering to pre-pandemic levels, American Express has grown revenue a total of 34%, free cash flow 35%, and net income 57% over the past 10 years. This total growth breaks down into low-single-digit annual rates.A valuation can influence a stock's returns, but American Express is likely to produce returns that mirror the pace the business is growing at over the long term. In other words, low-single-digit growth should eventually produce low-single-digit returns, which might not be good enough for many investors.2. Continued travel industry strugglesAmerican Express faces some challenges that could make it harder to rediscover a faster growth rate moving forward. The company's credit cards are popular for people who spend on travel and entertainment, which accounted for roughly a quarter of American Express' U.S. business before the pandemic.After travel began to rebound throughout 2020 as more of the population got vaccinated, the recent surge of the coronavirus omicron variant has already started to put a damper on travel once again.Nobody can predict the future; what is known is that the COVID-19 virus continues mutating, producing new variants. While vaccines and other medications continue arriving to help combat the pandemic, nobody can be sure how the coronavirus will continue to impact travel spending in the near term.American Express has reported that travel spending still lags pre-pandemic levels through three quarters of its 2021 fiscal year. Travel billings contributed 10% in the first quarter of 2021, 12% in the second quarter, and 14% in the third quarter. Investors will want to see fourth-quarter numbers to see how omicron has influenced travel. The coronavirus has been around for two years, so it's harder to discard the pandemic as a short-term business threat at this point.3. The buy now, pay later threatLooking further out, American Express remains threatened by the buy now, pay later (BNPL) competition rapidly heating up. Society is pivoting -- older consumers are quickly retiring, and younger generations such as Millennials are entering their prime earning and spending years.American Express reported that Millennials and Gen Z are now driving growth in its business. Spending among this age group is up 40% compared to pre-pandemic 2019 levels, while other age groups are at 10% growth or less. This underlines the importance that these young customers have to the long-term success of American Express and its competition.However, BNPL companies like Affirm, Klarna, and Afterpay have become very popular over the past year, especially with younger consumers. According to a study, 36% of BNPL users in the U.S. are under 25, and 41% are Millennials. Meanwhile, some experts predict that the BNPL market will grow 22% per year through 2028, and at least a chunk of this growth may be at the expense of traditional credit card companies like American Express.Get with the timesAmerican Express seems like an American classic that is past its prime. It may have staying power, continuing its low-single-digit growth rate, but in such a big consumer spending market, there should be better opportunities out there.By contrast, Affirm is one of my favorites. It has partnered with many of the leading e-commerce sites in the U.S., and that could place it among the largest benefactors of BNPL's rapid growth moving forward.","news_type":1},"isVote":1,"tweetType":1,"viewCount":872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691203813,"gmtCreate":1640189565031,"gmtModify":1640189565031,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"What happened","listText":"What happened","text":"What happened","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691203813","repostId":"1104039472","repostType":4,"repost":{"id":"1104039472","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640184691,"share":"https://www.laohu8.com/m/news/1104039472?lang=&edition=full","pubTime":"2021-12-22 22:51","market":"us","language":"en","title":"Biogen shares fell 1.2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104039472","media":"Tiger Newspress","summary":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inc","content":"<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen shares fell 1.2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen shares fell 1.2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104039472","content_text":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":997,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699385788,"gmtCreate":1639749919976,"gmtModify":1639749919976,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"Agree it will","listText":"Agree it will","text":"Agree it will","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699385788","repostId":"2192978346","repostType":4,"isVote":1,"tweetType":1,"viewCount":988,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699388028,"gmtCreate":1639749606635,"gmtModify":1639749606635,"author":{"id":"4088564397232090","authorId":"4088564397232090","name":"Galaxi","avatar":"https://static.tigerbbs.com/dd3756371cd52121c90555962187fdf7","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088564397232090","authorIdStr":"4088564397232090"},"themes":[],"htmlText":"[龇牙]&nbsp;","listText":"[龇牙]&nbsp;","text":"[龇牙]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699388028","repostId":"1116116501","repostType":4,"repost":{"id":"1116116501","pubTimestamp":1639745427,"share":"https://www.laohu8.com/m/news/1116116501?lang=&edition=full","pubTime":"2021-12-17 20:50","market":"us","language":"en","title":"5 Stocks Insiders Are Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1116116501","media":"Benzinga","summary":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view t","content":"<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.</p>\n<p>Below is a look at a few recent notable insider sales.</p>\n<p><b>LegalZoom.com</b></p>\n<ul>\n <li><b>The Trade:LegalZoom.com, Inc.</b>&nbsp;Chief Financial Officer Bertram Noel Watson&nbsp;<i>disposed a total of 69466 shares</i>&nbsp;at an average price of $15.65. The insider received $1,087,351.30 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Morgan Stanley maintained LegalZoom.com with an Equal-Weight and lowered the price target from $28 to $19.</li>\n <li><b>What LegalZoom.com Does:</b>LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States</li>\n</ul>\n<p><b>Arvinas</b></p>\n<ul>\n <li><b>The Trade:Arvinas, Inc.</b>&nbsp;Director Liam Ratcliffe&nbsp;<i>sold a total of 355705 shares</i>&nbsp;at an average price of $67.00. The insider received $23,833,380.68 from selling those shares.</li>\n <li><b>What’s Happening:</b>Arvinas and Pfizer recently posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).</li>\n <li><b>What Arvinas Does:</b>Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.</li>\n</ul>\n<p><b>Marvell Technology</b></p>\n<ul>\n <li><b>The Trade:Marvell Technology, Inc.</b>&nbsp;CEO and President Matthew Murphy&nbsp;<i>sold a total of 30000 shares</i>&nbsp;at an average price of $85.98. The insider received $2,579,400.00 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Marvell recently introduced industry's first 50G PAM4 DSP chipset for next generation 5G RAN optical fronthaul.</li>\n <li><b>What Marvell Technology Does:</b>Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications.</li>\n</ul>\n<p><b>Hewlett Packard Enterprise</b></p>\n<ul>\n <li><b>The Trade:Hewlett Packard Enterprise Company</b>&nbsp;SVP &amp; GM, HPC &amp; AI Business Group Justin Hotard&nbsp;<i>sold a total of 40012 shares</i>&nbsp;at an average price of $14.55. The insider received $582,174.60 from selling those shares.</li>\n <li><b>What’s Happening:</b>Hewlett Packard Enterprise recently reported worse-than-expected Q4 sales results.</li>\n <li><b>What Hewlett Packard Enterprise Does:</b>Hewlett Packard Enterprise is a supplier of IT infrastructure products and services. The company operates as three major segments.</li>\n</ul>\n<p><b>Ameren</b></p>\n<ul>\n <li><b>The Trade:Ameren Corporation</b>&nbsp;Chairman, President and CEO Warner L Baxter<i>sold a total of 68300 shares</i>&nbsp;at an average price of $87.31. The insider received $4,976,670.00 from selling those shares.</li>\n <li><b>What’s Happening:</b>BMO Capital recently maintained Ameren with an Outperform and raised the price target from $85 to $95.</li>\n <li><b>What Ameren Does:</b>Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves nearly 2.5 million electricity customers and roughly 1.0 million natural gas customers.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks Insiders Are Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks Insiders Are Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HPE":"慧与科技","ARVN":"Arvinas Holding Company LLC","LZ":"LegalZoom.com, Inc","AEE":"阿曼瑞恩","MRVL":"迈威尔科技"},"source_url":"https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116116501","content_text":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.\nBelow is a look at a few recent notable insider sales.\nLegalZoom.com\n\nThe Trade:LegalZoom.com, Inc. Chief Financial Officer Bertram Noel Watson disposed a total of 69466 shares at an average price of $15.65. The insider received $1,087,351.30 as a result of the transaction.\nWhat’s Happening:Morgan Stanley maintained LegalZoom.com with an Equal-Weight and lowered the price target from $28 to $19.\nWhat LegalZoom.com Does:LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States\n\nArvinas\n\nThe Trade:Arvinas, Inc. Director Liam Ratcliffe sold a total of 355705 shares at an average price of $67.00. The insider received $23,833,380.68 from selling those shares.\nWhat’s Happening:Arvinas and Pfizer recently posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).\nWhat Arvinas Does:Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.\n\nMarvell Technology\n\nThe Trade:Marvell Technology, Inc. CEO and President Matthew Murphy sold a total of 30000 shares at an average price of $85.98. The insider received $2,579,400.00 as a result of the transaction.\nWhat’s Happening:Marvell recently introduced industry's first 50G PAM4 DSP chipset for next generation 5G RAN optical fronthaul.\nWhat Marvell Technology Does:Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications.\n\nHewlett Packard Enterprise\n\nThe Trade:Hewlett Packard Enterprise Company SVP & GM, HPC & AI Business Group Justin Hotard sold a total of 40012 shares at an average price of $14.55. The insider received $582,174.60 from selling those shares.\nWhat’s Happening:Hewlett Packard Enterprise recently reported worse-than-expected Q4 sales results.\nWhat Hewlett Packard Enterprise Does:Hewlett Packard Enterprise is a supplier of IT infrastructure products and services. The company operates as three major segments.\n\nAmeren\n\nThe Trade:Ameren Corporation Chairman, President and CEO Warner L Baxtersold a total of 68300 shares at an average price of $87.31. The insider received $4,976,670.00 from selling those shares.\nWhat’s Happening:BMO Capital recently maintained Ameren with an Outperform and raised the price target from $85 to $95.\nWhat Ameren Does:Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves nearly 2.5 million electricity customers and roughly 1.0 million natural gas customers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}